Latest Insider Transactions at Arch Therapeutics, Inc. (ARTH)
This section provides a real-time view of insider transactions for Arch Therapeutics, Inc. (ARTH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Arch Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Arch Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 31
2023
|
Laurence Hicks Director |
BUY
Open market or private purchase
|
Indirect |
10,292
+50.0%
|
$0
$0.28 P/Share
|
|
Aug 31
2023
|
Terrence W Norchi PRESIDENT AND CHIEF EXECUTIVE |
BUY
Open market or private purchase
|
Direct |
6,862
+50.0%
|
$0
$0.28 P/Share
|
|
Aug 31
2023
|
Michael S Abrams CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
10,292
+50.0%
|
$0
$0.28 P/Share
|
|
Jul 06
2022
|
Terrence W Norchi PRESIDENT AND CHIEF EXECUTIVE |
BUY
Grant, award, or other acquisition
|
Direct |
72,435
+2.37%
|
-
|
|
Jul 06
2022
|
Laurence Hicks Director |
BUY
Grant, award, or other acquisition
|
Indirect |
108,652
+50.0%
|
-
|
|
Jul 06
2022
|
Michael S Abrams CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
108,652
+50.0%
|
-
|
|
Jul 30
2021
|
Dan Yrigoyen VICE PRESIDENT, SALES |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+50.0%
|
-
|